Drug profile · INN
thalidomide
THALOMID
thalidomide (THALOMID) is a crl4(crbn) e3 ubiquitin ligase inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — thalidomide
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 5
- Programs
- 12
- Data quality
- 0.84
Quick answer
thalidomide (THALOMID) is a crl4(crbn) e3 ubiquitin ligase inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
CRL4(CRBN) E3 ubiquitin ligase inhibitor
Primary target: CRL4(CRBN) E3 ubiquitin ligase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 10836721
Thalidomide analogs and methods of use
granted -
US 10730835
Thalidomide analogs and methods of use
granted -
US 8716315
Analogs of thalidomide as potential angiogenesis inhibitors
granted -
US 7973057
Thalidomide analogs
granted -
US 7320991
Analogs of thalidomide as potential angiogenesis inhibitors
granted
Frequently asked questions
What is thalidomide?
thalidomide (THALOMID) is a crl4(crbn) e3 ubiquitin ligase inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for thalidomide?
THALOMID is a marketed brand name for thalidomide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of thalidomide?
thalidomide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.